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Physiology of Menopause
There are a few possible mechanisms that are thought to
contribute to physiologic changes in menopausal women.
Prior to menopause, the hypothalamus secretes gonadotropin-releasing hormone (GnRH), which causes the pituitary
gland to produce and release follicle-stimulating hormone
(FSH) and luteinizing hormone (LH). Estradiol and progesterone, secreted by functioning ovarian follicles, decrease
levels of FSH and LH via negative feedback. In menopausal
women, ovarian follicles stop functioning and therefore do
not secrete estradiol and progesterone; this allows levels of
FSH and LH to rise, producing a state of hormonal imbalance.
It is postulated that increased levels of LH contribute to a
decline in cognitive function. 2 This theory is supported by
evidence that LH receptors are highly expressed in the hippocampus and that down-regulation of these receptors leads
to cognitive improvement even in the absence of estrogen.
Another theory is that estrogen raises levels of acetylcholine,
which is believed to improve cognitive functioning.3

Abstract
Menopause occurs as a result of decreased natural estrogen
production by the body. A variety of short-term and
long-term symptoms can occur during menopause, which
may significantly impact a woman's daily life. Hormone
therapy (HT) is commonly employed to alleviate these
unwanted symptoms and to regain balance of hormone levels. Options include estrogen-only or estrogen-progestin
combination therapy. While HT may help relieve symptoms
such as cognitive decline caused by menopause, it also
carries potential side effects. Although HT has shown a
potential benefit in women with Alzheimer's disease (AD),
overall outcomes measuring cognitive function improvement
are inconclusive. Therefore, HT should not be initiated solely
to improve cognition until further research is completed to
support this indication. HT, however, is still an effective
means to treat several other post-menopausal symptoms. It
is imperative for pharmacists and physicians to stay updated
on current research to appropriately assess the risks and
benefits of HT treatment on an individual patient basis.

Hormonal Therapy (HT)
Non-pharmacologic therapy can be used to alleviate menopausal symptoms; however, HT is frequently used in an attempt to correct the hormonal imbalance and relieve associated symptoms. The decision to initiate HT should be based
on individual patient parameters including menopausal
symptoms and risk factors for osteoporosis, cardiovascular
disease, breast cancer and/or thromboembolism.1 Each
woman should also be thoroughly educated on the potential
benefits and risks of HT before making a decision to initiate
treatment (Table 1). There are two main types of systemic
HT: estrogen-only and estrogen-progestin combination.
Estrogen-only therapy is for women who have had a hysterectomy. Estrogen-progestin combination is used in women
with an intact uterus to decrease the risk of endometrial cancer associated with estrogen use. In either situation, The
North American Menopause Society recommends using the

Introduction
Menopause results from decreased estrogen levels due to the
loss of functioning ovarian follicles. It is defined as a physiologic event occurring after 12 months of amenorrhea and signifies the end of reproductive years.1 The average woman
goes through menopause around the age of 51 and experiences a variety of short-term symptoms, which may include
problems with concentration and memory as well as an increased risk of developing long-term health issues such as
osteoporosis and coronary artery disease. Both short-term
and long-term menopausal effects can significantly impact a
woman's quality of life, but with proper management, shortterm symptoms can be effectively alleviated and long-term
risks can be minimized.

Table 1. Potential Benefits, Risks and Side Effects of HT1
Benefits

Risks*

• Ovarian cancer
• Decrease hot flashes and
• Endometrial cancer
night sweats
• Improve vaginal atrophy
• Breast cancer
• Venous thromboem• Prevent and treat osteobolism
porosis
• Gallbladder disease
• Reduce risk of colorectal
• Cardiovascular disease
cancer
*Risks are influenced by type of HT along with patientspecific risk factors
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Side effects of estrogen
•
•
•
•

Nausea
Headache
Breast tenderness
Heavy bleeding

To decrease use lower
doses and/or transdermal
estradiol
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Side effects ofprogestin

• Irritability

•

Depression
• Headache
• Mood swings
• Bloating
• Fluid retention
• Sleeo disturbances
Vary with type ofprogestin
and route of administration
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lowest dose of HT necessary to relieve the patient's symp·
toms, as lower doses minimize risks.4 Both types of systemic
HT have proven beneficial to alleviate vasomotor symptoms
(hot flashes and night sweats), decrease vaginal atrophy, and
prevent osteoporosis. However, there have been controversial studies regarding the effectiveness of HT to improve
other menopausal symptoms, including cognitive decline. 4

function; whether it will cause a further decline, or serve to
protect against additional deterioration. This is an important
issue due to the fact that many more women are working
into their menopausal and post-menopausal years. A survey
of some available research on the topic has been conducted
to determine the effects of HT on a woman's cognitive function.

Cognition
Cognition includes a range of higher-level brain functions,
especially those involved with the ability to learn and recall
information. To evaluate cognition, subjects are tested in
their ability to organize, plan, and solve problems with given
information, as well as perform calculations. The ability to
focus, maintain, and shift one's attention as necessary is also
a major component. Other tests are given to show depth of
understanding and usage of language, as well as the ability to
perceive an environment in a correct manner.s Cognitive decline is often associated with aging and the advancement of
dementia or Alzheimer's disease (AD). Patients may begin
noticing changes such as worsened memory, language barriers, thinking impairment, and reduced judgment as cognition
begins to decline. These impairments may also be associated
with feelings of depression, irritability and aggression, anxiety or apathy.6

A prospective cohort study enrolled 2,859 women who formerly used estrogen replacement therapy and tested them
by the DWR, DSS/WAIS-R, and WF tests to analyze association of hormone replacement therapy with cognition in postmenopausal women.7 More participants were found to have
surgically-induced menopause (69 percent) versus natural
menopause (22 percent). Average users of HT were found to
be younger, Caucasian, and more educated than nonusers of
HT. This study found no association between estrogen replacement therapy and cognition, though evidence was found
in animal models showing improved cognition decline. One
possible confounder is the young age (mean age 56.6 years
SD ±5.5) of many of the participants.

Mental status tests are usually performed to assess the existence of cognitive decline. These tests are generally quick,
involving tasks and questions. The Delayed Word Recall Test
(DWR) tests verbal learning and short-term memory. Subjects are asked to remember 10 common nouns after a fiveminute interval during which other tests are administered.
To standardize results, respondents are to phrase sentences
containing the 10 words and are then given a score based on
the number of recalled words out of 10 (0-10).7The Digit
Symbol Subtest of the Wechsler Adult Intelligence ScaleRevised (DSS/WAIS-R) test involves a timed translation of
numbers (1-9) to symbols following a key. It is used to measure psychomotor performance and is unaffected by intelligence, memory or learning in most people. This test may be
used to measure brain damage and scores are based on the
number of correctly transcribed numbers to symbols in 90
seconds (high score of 93).7 The Word Fluency Test (WF)
requires participants to list as many words as possible beginning with a certain letter of the alphabet within 60 seconds.
The test is sensitive to linguistic impairment and early mental decline in older adults, usually involving three trials with
three separate letters.7The Vuschnke-Fuld Selective Reminding Test tests storage, retention and retrieval of spoken
words; the subject is read 10 words and she must repeat as
many as possible.BVisual Reproduction Tests assess memory
for geometric forms; in this test patients must reproduce
three stimuli immediately and again after a half hour.BA
Blessed Information Memory Control Test assesses a subject's mental control; in these tests subjects must do things
such as recite the months backwards and recall a name and
address after a 10 minute delay.B
Clinical Trials
Patients have questioned how HT will affect their cognitive
January 2012 Volume 3, Issue 1

In a randomized, controlled trial, 64 postmenopausal participants (27 HT, 37 non-HT) were matched for age, level of education, and postmenopausal period.9 The HT group had to
meet inclusion criteria of natural menopause and to have
used HT for at least one year. Of the HT arm, 70.37 percent
were given estrogenic treatment, either Premarin®
(conjugated estrogens) or Estraderm® (estradiol), and 29.63
percent were given Livial® (tibolone), an estrogenic, progestogenic, and androgenic combination hormone. A group
of 44 scored tests were used to measure cognitive functions,
including immediate and delayed visual and verbal memory,
visuospatial perception and orientation, prolonged attention/vigilance, visual search and scan, impulsivity and response speed, executive functions and general intelligence.
Mental status tests used included Wechsler Memory ScaleRevised, Line Orientation Test, Cancellation Test and Raven
Standard Progressive Matrices. After statistical analysis of
the results, even though controlled techniques were applied,
no relationship could be observed between HT and cognitive
function.
A prospective cohort study of 83 women in Israel indicated
no negative effect on cognitive function due to the use of
HT.to Inclusion and exclusion criteria for this study were
strict. Women with surgically-induced menopause were specifically excluded, as were women with known dementia or
who were being treated for cognitive decline, women using
HT for <5 years, and women suffering from a few other
known medical conditions. Inclusion in the study involved
being aged 55-60, of Ashkenzai Jewish ethnicity, and a minimum of a university/ college education. Of those participating
in the study, 40 (48.2 percent) had never used HT. The remaining 43 users of HT included 87.5 percent of women
treated with combination estrogen and progestin. A battery
of computerized tests was run on each participant. This
study demonstrated no significant difference between cognitive function in HT users and nonusers when measuring cognitive function via computerized cognitive battery.
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A meta-analysis conducted by the American Medical Association (AMA) has categorized the research that has been performed on this topic.11 The study compared the results from
randomized controlled trials (RCTs) and cohort studies in
the areas of verbal recall, visual memory, working memory,
vigilance, concept formation and reasoning, motor speed,
dementia screening measures and verbal function. It also
compared the findings for the use of HT in the prevention of
AD. Most results for each category were inconclusive; it
seemed that each study came to a different conclusion. The
area suggesting the most correlation with HT was in the prevention of AD, which showed no negative opposing results;
however, this study area included no RCTs. The analysis also
revealed that the use of estrogen-progestin combination was
not shown to enhance the effects of estrogen in the possible
improvement of cognitive function.

Conclusion and Pharmacy Implications
The majority of studies provided inconclusive results regarding the effects of HT on cognitive function in postmenopausal
women. There may be a possible link between HT and the
prevention of AD, but more research is needed before a definitive connection can be made. An AMA review found that
progestin had no additional benefits to improve cognitive
function when used with estrogen.11 Some women choose
not to use HT because they wish to stay medication free,
want to avoid potential side effects such as breast tenderness
or weight gain, question HT efficacy due to controversial
findings or are concerned about the potential increased risk
for developing certain types of cancer.12
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Pharmacists and physicians can assist each woman to weigh
the benefits and risks of HT and allow her to make an educated decision. The decision to initiate HT can be based on
the severity of the symptoms the patient is experiencing. If
symptoms are too problematic to manage with nonpharmacological treatment, HT therapy may be helpful if
benefits outweigh potential side effects. A patient's fears
should also be taken into consideration; if the patient feels
her symptoms are only a minor disturbance to her daily living, risks of HT should be taken into account before a decision is reached. Ultimately, the decision to use HT should be
the patient's choice and only made after evaluating all possible outcomes. Physicians should not regularly prescribe HT
to prevent cognitive decline until further evidence demonstrates efficacy. Even though HT may not be beneficial for
cognition, it may offer relief of other menopausal symptoms.
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